Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary at 
CorMedix
CorMedixExecutive
About Beth Zelnick Kaufman
Beth Zelnick Kaufman is Executive Vice President, Chief Legal and Compliance Officer, and Corporate Secretary of CorMedix Inc. (CRMD). She joined CorMedix as EVP and Chief Legal Officer and Corporate Secretary in December 2023 and assumed the combined Legal and Compliance role in December 2024 . She has more than two decades of legal, compliance, and operations experience across Akorn Pharmaceuticals (Chief Legal & Administrative Officer and Corporate Secretary), The Broad Institute of MIT and Harvard (Chief Legal Officer), and Amneal Pharmaceuticals (Assistant General Counsel; Vice President, Legal Affairs; Head of Government Affairs), with earlier roles at Actavis, Alpharma, Topcon America, and Brown Rudnick LLP . As of April 25, 2025, she was 65 years old and served among CRMD’s executive officers .
- Role/tenure: EVP, Chief Legal and Compliance Officer and Corporate Secretary; EVP and Chief Legal Officer since Dec 2023; Compliance added Dec 2024
- Age: 65 (as of April 25, 2025)
- Beneficial ownership: 66,487 shares and 50,000 options (less than 1% of outstanding)
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Akorn Pharmaceuticals | Chief Legal & Administrative Officer; Corporate Secretary | — | Senior legal, administrative leadership in specialty/generic pharma |
| The Broad Institute of MIT and Harvard | Chief Legal Officer | — | Led legal function at a premier biomedical research institute |
| Amneal Pharmaceuticals | Assistant General Counsel; VP, Legal Affairs; Head of Government Affairs | — | Advanced legal, regulatory and government affairs at a global generics/biosimilars/branded company |
| Actavis; Alpharma; Topcon America | Legal roles | — | Earlier industry legal roles |
| Brown Rudnick LLP | Associate | — | Law firm training/experience |
External Roles
- None disclosed for public-company directorships or committee roles in the company’s proxy statements; executive biography lists only CRMD role and prior employment history .
Fixed Compensation
- Not disclosed for Ms. Zelnick Kaufman. She is not listed as a Named Executive Officer (NEO) in the 2024 or 2025 Summary Compensation Tables; therefore, base salary, target bonus, and actual bonus amounts for her are not provided in the proxy .
Performance Compensation
- Individual performance metrics and payouts for Ms. Zelnick Kaufman are not disclosed.
- Equity plan features (company-wide): CRMD’s Amended & Restated 2019 Omnibus Stock Incentive Plan authorizes options, RSUs, SARs, restricted stock, and other awards; prohibits option/SAR repricing without shareholder approval; and includes clawback and change-in-control provisions administered by the Board/Compensation Committee .
- Plan share pool actions:
- October 2024: shareholders approved increasing the plan reserve to 8,160,000 shares .
- October 2025 special meeting proxy seeks to increase to 12,472,000 shares (an additional 4,312,000 shares) .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Total beneficial ownership | 66,487 common shares; 50,000 stock options (less than 1% of outstanding) |
| Shares outstanding reference | 67,810,476 common shares outstanding as of April 25, 2025 |
| Hedging/pledging | Company policy restricts hedging/monetization, prohibits short sales, and strongly discourages pledging/margin accounts |
| Clawback | Mandatory clawback policy adopted Dec 2023 for restatements; discretionary recoupment for misconduct; applies to executive officers |
| Ownership guidelines | Director stock ownership guidelines disclosed (for non-employee directors). No executive ownership guideline disclosure identified . |
Employment Terms
- Employment start and role changes: Appointed EVP and Chief Legal Officer and Corporate Secretary on December 12, 2023; added Compliance in December 2024 .
- Company-wide compensation governance: Independent Compensation Committee oversees executive pay; Frederic W. Cook & Co. retained as independent compensation consultant .
- Clawback and anti-hedging policies: As above; no tax gross-ups disclosed; no related-party transactions reported .
Governance and Shareholder Signals
| Topic | 2025 outcome/data | Notes |
|---|---|---|
| Say-on-Pay (2025, FY2024 comp) | For: 16,086,287; Against: 1,999,311; Abstain: 360,596; Broker non-votes: 27,599,135 | Advisory approval indicates shareholder support for NEO pay program |
| Equity pool expansion (Oct 2025 special) | Plan increase +4,312,000 to 12,472,000 shares | Potential dilution estimate disclosed at 4.6% of fully diluted shares |
| No repricing policy | Repricing of options/SARs requires shareholder approval | Reinforces shareholder-friendly plan guardrails |
| Related-party transactions | None reported in latest proxies | Reduces governance red-flag risk |
Data Extracts
Ownership snapshot (as of April 25, 2025)
| Metric | Value |
|---|---|
| Shares owned | 66,487 |
| Options | 50,000 |
| % of outstanding | <1% (based on 67,810,476 shares outstanding) |
Compensation governance
| Policy | Key terms |
|---|---|
| Hedging/short sales | Restricted/prohibited under insider trading policy |
| Pledging/margin | Strongly discouraged |
| Clawback | Mandatory (restatement) and discretionary (misconduct) recoupment frameworks (executive officers) |
| Equity plan | Options/RSUs/SARs allowed; no repricing without shareholder approval |
Investment Implications
- Alignment: Beneficial ownership is modest (<1%), but company-wide policies (clawback, anti-hedging/pledging, no-repricing) and continued equity plan funding support long-term alignment via equity-based incentives .
- Disclosure gap: As a non-NEO, her individual base salary, bonus targets, and performance conditions are not disclosed; this limits pay-for-performance assessment at the individual level .
- Dilution/trading signals: The 2025 plan share increase (+4.312M shares; 4.6% of fully diluted) expands the incentive pool—constructive for retention but a potential dilution overhang if broadly granted; no individual vesting schedules or option strike details are disclosed for Ms. Zelnick Kaufman .
- Shareholder sentiment: Strong say-on-pay support in 2025 indicates broader investor acceptance of executive compensation design and governance controls, which lowers governance risk backdrop for the leadership team, including legal/compliance leadership .